Jung Min (Leo) Lee, MD

 Rm. S427, S-BST
200 Lothrop street
Pittsburgh, PA 15261
jmlee@pitt.edu
412-648-8146

Research Interests

  1. The role of β-catenin and PDGFR-a signaling in liver regeneration and cancer.
  2. Role of glutamine synthetase as a surrogate marker in predicting β- catenin mutated hepatoceullar carcinoma.

Reviews

  1. JM Lee, SH Ahn. Quantification of HBsAg: Basic virology for clinical practice. World J Gastroenterol. 2011 Jan;17(3):283- 289.
  2. JM Lee, K-H Han. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. Oncology. 2010 Jul;78 Suppl 1:167-71.
  3. JM Lee, K-H Han, SH Ahn. Ascites and spontaneous bacterial peritonitis: an Asian perspective. J Gastroenterol Hepatol. 2009 Sep;24(9):1494-503.

Publications

  1. Park H, JM Lee, Seo JH, et al. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int. 2011 Nov 30. [Epub ahead of print]
  2. JM Lee, SH Ahn, HS Kim, et al. Quantitative HBsAg and HBeAg assays in the prediction of virologic response to entecavir in patients with chronic hepatitis B. Hepatology. 2011;53:1486- 1493.
  3. Lee MH, Kim DY, Kim JK, Chang HY, Kang SH, Ryu HJ, Ju HL, Kim SU, JM Lee, et al. Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. Intervirology. 2011 Aug 24. [Epub ahead of print]
  4. Jung J, Lee HJ, JM Lee, Na KH, Hwang SG, Kim GJ. Placenta extract promote liver regeneration in CCl(4)-injured liver rat model. Int Immunopharmacol. 2011 Aug;11(8):976-84.
  5. Kim SU, Park JY, Kim DY, Ahn SH, Choi EH, Seok JY, JM Lee, Park YN, Chon JY, Han KH. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int. 2010; 4: 673-680
  6. SU Kim, DY Kim, SH Ahn, HM Kim, JM Lee, et al. The Impact of Steatosis in Liver Stiffness Measurement in Patients with Chronic Hepatitis B. Hepato-gastroenterology. 2010;57:1-6.
  7. HJ Ryu, JM Lee (Co-primary), et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842.
  8. YK Park, JM Lee, DY Kim, HY Chang, JK Kim, CK Lee, et al. Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B. Dig Dis Sci. 2010 Jul;55(7):2043-8.
  9. JM Lee, JH Cheon, JJ Park, et al. Effects of hyosine N-butyl bromide on the detection of polyps during colonoscopy. Hepato- gastroenterology. 2010;57(97):90-4.
  10. JM Lee, JY Park, DY Kim, et al. Long-term Adefovir Dipivoxil Monotherapy for up to 5 Years in Lamivudine-resistant Chronic Hepatitis B. Antivir Ther. 2010;15(2):235-241.
  11. JK Kim, HY Chang, JM Lee, YJ Yoon, JY Park, DY Kim, et al. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol. 2009 Jun;81(6):1002-1008
  12. DY Kim, SU Kim, SH Ahn, JY Park, JM Lee, YN Park, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci. 2009;54:1758-1763.
  13. SU Kim, JK Kim, JY Park, SH Ahn, JM Lee, O Baatarkhuu, et al. Variability in liver stiffness values from different intercostal spaces. Liver Int. 2009;29:760-766.
  14. JM Lee, HJ Kim, JY Park, et al. Rescue monotherapy in lamivudine-resistant HBeAg positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther. 2009;14(5):705-712.